Skip to Content
800-533-8762
  • Careers
  • Newsroom
  • Health Care Professionals
  • About Us
  • Contact Us
UPMC
  • Find a Doctor
  • Services
    • Frequently Searched Services
    • Frequently Searched Services
      Allergy & Immunology Behavioral & Mental Health Cancer Ear, Nose & Throat Endocrinology Gastroenterology Heart & Vascular Imaging Neurosciences Orthopaedics
      Physical Rehabilitation Plastic & Reconstructive Surgery Primary Care Senior Services Sports Medicine Telemedicine Transplant Surgery Walk-In Care Weight Management Women’s Health
      See all Services
    • Services by Region
    • Find a UPMC health care facility close to you quickly by browsing by region.
      UPMC in Western Pa. Western Pa. and New York
      UPMC in Central Pa. Central Pa.
      UPMC in North Central Pa. North Central Pa.
      UPMC in Western Md. Maryland & West Virginia
    • See All Services
  • Locations
    • Locations by Type
    • Locations by Type
      UPMC hospitals
      Hospitals
      Physical Therapy
      Physical Therapy
      Urgent care
      Walk-In Care
      UPMC Outpatient Centers
      Outpatient Centers
      UPMC Imaging Services
      Imaging
      Community Health Centers
      Community Health Centers
      See All Locations
    • Locations by Region
    • Locations by Region
      UPMC in Southwest Pa. Southwest Pa.
      UPMC in North Central Pa. North Central Pa.
      UPMC in Northwest Pa and Ny. Northwest Pa. & Western N.Y.
      UPMC in West Central Pa. West Central Pa.
      UPMC in Central Pa. Central Pa.
      UPMC in Western Md. Maryland & West Virginia
    • See All Locations
  • Patients & Visitors
    • Patient & Visitor Resources
    • Patient & Visitor Resources
      Patients and Visitors Resources Pay a Bill Classes & Events Medical Records Health Library Patient Information
      Patient Portals Privacy Information Shared Decision Making Traveling Patients Visitor Information
      Man uses mobile phone
      Pay a Bill
      Nurse reviews medical chart
      Request Medical Records
  • Patient Portals
  • Find Covid-19 updates
  • Schedule an appointment
  • Request medical records
  • Pay a bill
  • Learn about financial assistance
  • Find classes & events
  • Send a patient an eCard
  • Make a donation
  • Volunteer
  • Read HealthBeat blog
  • Explore UPMC Careers
Skip to Content
UPMC
  • Patient Portals
  • For Patients & Visitors
    • Find a Doctor
    • Locations
    • Patient & Visitor Resources
    • Pay a Bill
    • Services
    • More
      • Medical Records
      • Financial Assistance
      • Classes & Events
      • HealthBeat Blog
      • Health Library
  • About UPMC
    • Why UPMC
    • Facts & Stats
    • Supply Chain Management
    • Community Commitment
    • More
      • Financials
      • Support UPMC
      • UPMC Apps
      • UPMC Enterprises
      • UPMC International
  • For Health Care Professionals
    • Physician Information
    • Resources
    • Education & Training
    • Departments
    • Credentialing
  • Careers
  • Contact Us
  • Newsroom
  • UPMC >
  • Media Relations >
  • News Releases >
  • burgess asco
Media Relations
News Releases
Central Pa. News
North Central Pa. News
Contact Us
Experts
Community-Focused News
Media Kits
Media RSS
Media Relations
News Releases
Central Pa. News
North Central Pa. News
Contact Us
Experts
Community-Focused News
Media Kits
Media RSS

Chat Keywords List

  • cancel or exit: Stops your conversation
  • start over: Restarts your current scenario
  • help: Shows what this bot can do
  • terms: Shows terms of use and privacy statement
  • feedback: Give us feedback
Continue
Chat with UPMC
RESTART
MENU
CLOSE

​Immunotherapy Effective Against Some Types of Sarcoma

For Journalists

Allison Hydzik
Director, Science and Research
412-647-9975
hydzikam@upmc.edu

Wendy Zellner
Vice President
412-586-9777
zellnerwl@upmc.edu

Want to Make an Appointment or Need Patient Information?
Contact UPMC at

1-800-533-8762.

Go to Find a Doctor to search for a UPMC doctor.

UPMC color stacked

6/5/2016

PITTSBURGH, June 5, 2016 - An existing cancer immunotherapy drug reduces tumor size in some types of rare connective tissue cancers, called sarcomas, report researchers at the University of Pittsburgh Cancer Institute (UPCI). Additional analyses of tumor biopsies and blood samples, which will help the researchers better understand which sarcoma subtypes will benefit most from the new treatment, are underway.

Interim results from the phase II clinical trial were presented today at the 52nd annual American Society of Clinical Oncology (ASCO) annual meeting in Chicago by principal investigator Hussein Abdul-Hassan Tawbi, M.D., Ph.D., formerly of UPCI and current associate professor, University of Texas MD Anderson Cancer Center.

Sarcoma is a rare disease, encompassing less than 1 percent of adult cancers, and the available treatments are limited, so the need for new therapies is high, explained the current lead investigator for the Pittsburgh site, Melissa Burgess, M.D., assistant professor of medicine at UPCI.

"This is a pivotal trial for sarcoma, the first and largest trial to be conducted using this specific immunotherapeutic approach. What makes this trial special is that we collected biopsies and blood samples to really study how the treatment is working or not working in these patients. These immune monitoring studies will offer unique insights into the biology of immunotherapy in sarcoma," Dr. Burgess said.

Immunotherapies work by using a patient's own immune cells to target cancer cells. The new trial examined the safety and effect of pembrolizumab, which currently is approved for use in advanced melanoma and certain types of advanced lung cancer, on tumor size in four types of soft tissue sarcomas and three types of bone sarcomas.

UPCI, the first of 12 sites to enroll subjects, contributed approximately one quarter of the 80 total patients. Patients received the drug every three weeks. Tumor assessments began at eight weeks and were conducted every 12 weeks thereafter. The trial enrolled on a rolling basis, and is still in progress, so in these results, not all patients have received the drug for the same amount of time.

About 20 percent of patients in the combined soft tissue sarcoma group showed a reduction in tumor size during at least one time point. However, when the researchers looked at the sarcoma subtypes individually, they found one with especially promising results: 44 percent of patients with undifferentiated pleomorphic sarcoma experienced a reduction in tumor size. Encouraging improvements in tumor size also were found in two subtypes of bone sarcomas, osteosarcoma and chondrosarcoma, Dr. Burgess noted.

"Unfortunately, these early results suggest that there is limited efficacy of pembrolizumab in the patient population as a whole. However, it's promising that the drug seems to be beneficial in specific sarcoma subtypes. Our ongoing immune monitoring studies will allow us to better characterize the patients who will most benefit from this therapy for future clinical trials," said Dr. Burgess.

Additional co-authors of the trial trial include Denise K. Reinke, M.S., N.P., M.B.A., of SARC, which coordinated the trial; John Crowley, Ph.D., of Cancer Research and Biostatistics; Brian Van Tine, M.D., Ph.D., of Washington University in St. Louis; James Hu, M.D., of University of Southern California Norris Comprehensive Cancer Center; Scott Schuetze, M.D., and Laurence Baker, D.O., of University of Michigan; Sandra D'Angelo, M.D., of Memorial Sloan Kettering Cancer Center; Steven Attia, D.O., of Mayo Clinic Jacksonville, Dennis Priebat, M.D., of MedStar Washington Hospital Center; Scott Okuno, M.D., of Mayo Clinic, Rochester; Richard Riedel, M.D., of Duke University Medical Center, Lara Davis, M.D., of Oregon Health and Sciences University; Sujana Movva, M.D., of Fox Chase Cancer Center; Damon Reed, M.D., of Moffitt Cancer Center; Robert Maki, M.D., Ph.D., of Tisch Cancer Institute; and Shreyaskumar Patel, M.D., of University of Texas MD Anderson Cancer Center.

Funding for the trial was provided by Merck & Co., the maker of pembrolizumab, Sarcoma Alliance for Research Through Collaboration, Sarcoma Foundation of America and QuadW Foundation. Funding for the ongoing studies was partially provided by local philanthropic support group Pittsburgh Cure Sarcoma.

UPMC
200 Lothrop Street Pittsburgh, PA 15213

412-647-8762 800-533-8762

Patients And Visitors
  • Find a Doctor
  • Locations
  • Pay a Bill
  • Patient & Visitor Resources
  • Disabilities Resource Center
  • Services
  • Medical Records
  • No Surprises Act
  • Price Transparency
  • Financial Assistance
  • Classes & Events
  • Health Library
Health Care Professionals
  • Physician Information
  • Resources
  • Education & Training
  • Departments
  • Credentialing
Newsroom
  • Newsroom Home
  • Inside Life Changing Medicine Blog
  • News Releases
About
  • Why UPMC
  • Facts & Stats
  • Supply Chain Management
  • Community Commitment
  • Financials
  • Supporting UPMC
  • HealthBeat Blog
  • UPMC Apps
  • UPMC Enterprises
  • UPMC Health Plan
  • UPMC International
  • Nondiscrimination Policy
Life changing is...
Follow UPMC
  • Contact Us
  • Website/Email Terms of Use
  • Medical Advice Disclaimer
  • Privacy Information
  • Active Privacy Alerts
  • Sitemap
© 2025 UPMC I Affiliated with the University of Pittsburgh Schools of the Health Sciences Supplemental content provided by Healthwise, Incorporated. To learn more, visit healthwise.org
Find Care
Providers
Video Visit
Portal Login